Please ensure Javascript is enabled for purposes of website accessibility

FDA Approves New Prostate Cancer Treatment From AstraZeneca and Merck

By Cory Renauer – May 20, 2020 at 4:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Lynparza could generate blockbuster sales as a new treatment option that isn't hormone-based.

Members of a large subset of prostate cancer patients with tumors that have already spread have a new chemotherapy-free treatment option. The FDA on Wednesday approved Lynparza, a PARP inhibitor from AstraZeneca (AZN 2.29%) and Merck (MRK 0.67%) that previously had been approved to treat people with ovarian and breast cancers.  

Not surprising 

The FDA completed its review of Lynparza for prostate cancer patients with tumors that test positive for homologous recombination repair (HRR) mutations a couple of months ahead of schedule. While the approval wasn't surprising, the FDA's decision came much more swiftly than expected.

Scientist looking at a colorful report.

Image source: Getty Images.

During the clinical trial that AstraZeneca and Merck ran to support Lynparza's label expansion, patients treated with Lynparza were 66% less likely to die or show signs of disease progression than those given Xtandi from Astellas Pharma and Pfizer (PFE 0.50%) or Zytiga from Johnson & Johnson (JNJ 1.16%).

Another blockbuster label expansion

Annual Lynarza sales climbed 85% higher in 2019 thanks to previous label expansions, and 2020 sales could surge in response to demand from a large underserved prostate cancer population. Prostate cancer's the second-most-commonly diagnosed malignancy among men in the U.S., and patients have up until now lacked treatment options if hormonal therapy stops working for them.  

The already-popular hormonal treatments will continue to play important roles in the treatment of prostate cancer, but patients need better options once these blockbuster drugs from Johnson and Johnson and Pfizer can't stop their disease from progressing. As a PARP-inhibitor that makes it hard for tumor cells to fix their own genetic material, rather than another hormone-based treatment, Lynparza could be in high demand in this indication. 

Cory Renauer owns shares of Johnson & Johnson. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$88.14 (0.67%) $0.58
AstraZeneca PLC Stock Quote
AstraZeneca PLC
$56.82 (2.29%) $1.27
Pfizer Inc. Stock Quote
Pfizer Inc.
$44.36 (0.50%) $0.22
Johnson & Johnson Stock Quote
Johnson & Johnson
$165.09 (1.16%) $1.89

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.